Tandem Diabetes Care Inc’s recent filing unveils that its Director Allen Dick acquired Company’s shares for reported $94778.0 on Nov 27 ’23. In the deal valued at $18.96 per share,5,000 shares were bought. As a result of this transaction, Allen Dick now holds 19,962 shares worth roughly $0.61 million.
Then, Vosseller Leigh bought 6,200 shares, generating $95,395 in total proceeds. Upon buying the shares at $15.39, the EVP & CHIEF FINANCIAL OFFICER now owns 11,860 shares.
Before that, Hansen Shannon Marie bought 1,935 shares. Tandem Diabetes Care Inc shares valued at $29,884 were divested by the Chief Legal Officer at a price of $15.44 per share. As a result of the transaction, Hansen Shannon Marie now holds 1,935 shares, worth roughly $58882.05.
Stifel upgraded its Tandem Diabetes Care Inc [TNDM] rating to a Buy from a a Hold in a research note published on March 26, 2024; the price target was increased to $37 from $24. A number of analysts have revised their coverage, including Citigroup’s analysts, who decreased its forecast for the stock in early August from “a Buy” to “a Neutral”. BofA Securities also remained covering TNDM and has decreased its forecast on May 05, 2023 with a “an Underperform” recommendation from previously “Neutral” rating. Raymond James revised its rating on April 24, 2023. It rated TNDM as “a Mkt perform” which previously was an “an Outperform”.
Price Performance Review of TNDM
On Friday, Tandem Diabetes Care Inc [NASDAQ:TNDM] saw its stock fall -1.62% to $30.43. Over the last five days, the stock has lost -9.16%. Tandem Diabetes Care Inc shares have risen nearly 2.87% since the year began. Nevertheless, the stocks have fallen -26.18% over the past one year. While a 52-week high of $41.22 was reached on 03/28/24, a 52-week low of $13.82 was recorded on 01/31/24. SMA at 50 days reached $29.67, while 200 days put it at $25.60. A total of 0.99 million shares were traded, compared to the trading of 1.1 million shares in the previous session.
Levels Of Support And Resistance For TNDM Stock
The 24-hour chart illustrates a support level at 30.01, which if violated will result in even more drops to 29.58. On the upside, there is a resistance level at 31.12. A further resistance level may holdings at 31.81. The Relative Strength Index (RSI) on the 14-day chart is 44.39, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.03, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 96.77%. Stochastics %K at 6.63% indicates the stock is a buying.
The most recent change occurred on March 29, 2023 when UBS began covering the stock and recommended ‘”a Neutral”‘ rating along with a $45 price target.
